Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

Phase 1

Conditions: Congestive Heart Failure
Essential Hypertension
Chronic Stable Angina

Interventions: Drug: Dilatrend SR capsule 32mg
Drug: Dilatrend IR tablet 25mg

First Posted Date: 2013-03-28

Last Posted Date: 2013-04-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT01819870

Locations: 🇰🇷
Kyungpook National University Hospital Clinical Trial Center, Daegu, eok-dong 2(i)-ga Jung-gu, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)

Phase 4

Terminated

Conditions: Hypertension

Interventions: Drug: Candemore tablet
Drug: Cozzar tablet

First Posted Date: 2013-01-11

Last Posted Date: 2014-03-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT01766505

Locations: 🇰🇷
Presbyterian Medical Center, Chunju, Korea, Republic of
🇰🇷
Chunbuk National University Hospital, Chonju, Korea, Republic of
🇰🇷
Chungnam national university hospital, Daejeon, Korea, Republic of

and more 6 locations

The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

Phase 4

Conditions: Evidence of Liver Transplantation

Interventions: Drug: Mycophenolate mofetil

First Posted Date: 2013-01-11

Last Posted Date: 2013-11-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 120

Registration Number: NCT01766518

Locations: 🇰🇷
Seoul ST Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Asan medical center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

Phase 4

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Imotun
Drug: Placebo

First Posted Date: 2012-12-28

Last Posted Date: 2017-03-27

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 287

Registration Number: NCT01756937

Locations: 🇰🇷
Yeungnam university medical center, Daegu, Korea, Republic of
🇰🇷
hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Chung-Ang University hospital, Seoul, Korea, Republic of

and more 6 locations

Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Carvedilol SR 32mg, QD
Drug: Carvedilol IR 25mg, QD
Drug: Carvedilol SR 64mg, QD
Drug: Carvedilol IR 25mg, BID

First Posted Date: 2012-12-27

Last Posted Date: 2014-01-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 238

Registration Number: NCT01756430

Locations: 🇰🇷
The Hanyang Universitiy Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of

Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tacrolimus with Methotrexate

First Posted Date: 2012-12-11

Last Posted Date: 2015-08-11

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 111

Registration Number: NCT01746680

Locations: 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

Phase 4

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Imotun capsule
Drug: Imotun capsule placebo

First Posted Date: 2012-12-06

Last Posted Date: 2015-04-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 234

Registration Number: NCT01743287

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷
Bundang CHA medical center, Seongnam, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 7 locations

Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers

Phase 1

Completed

Conditions: Anemia

Interventions: Drug: NESP 60μg
Drug: CKD-11101 60μg

First Posted Date: 2012-09-14

Last Posted Date: 2017-05-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 34

Registration Number: NCT01685671

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers

Phase 1

Completed

Conditions: Anemia

Interventions: Drug: NESP 60μg
Drug: CKD-11101 60μg

First Posted Date: 2012-09-13

Last Posted Date: 2017-05-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 31

Registration Number: NCT01684605

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

Phase 4

Completed

Conditions: Hypertension
Congestive Heart Failure

Interventions: Drug: Candemore tablet
Drug: Atacand tablet

First Posted Date: 2012-09-11

Last Posted Date: 2015-09-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 169

Registration Number: NCT01682564

Locations: 🇰🇷
Daegu catholic univ. medical center, Daegu, Nam-gu Daemyung-dong, Korea, Republic of
🇰🇷
Maryknoll medical center, Busan, Jung-gu Daecheong-dong, Korea, Republic of
🇰🇷
Gyeongsang national university hospital, Jinju, Chiram-dong, Korea, Republic of

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy